598P A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Fred Hutch Cancer Center, Duke University, Duke Cancer Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Epic Sciences (United States), Vancouver Prostate Centre, Sidney Kimmel Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: American Association for Cancer Research, Gateway for Cancer Research, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Celgene, Genomic Health, Movember Foundation, Taiho Pharmaceutical, Exelixis, Clovis Oncology, Acceleron, Constellation Pharmaceuticals, Calithera Biosciences, Advanced Accelerator Applications, Astellas Pharma, Ipsen, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Genentech, EMD Serono, Janssen Biotech, Daiichi Sankyo Europe
OpenAlex ID: W3203550535